Trastuzumab

BioDrugs

Volumn 12, Issue 2, 1999, Pages 129-135

  Perry, Caroline M ^a   Wiseman, Lynda R ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DOXORUBICIN; GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; DRUG MECHANISM; DRUG TOLERABILITY; FEVER; HEADACHE; HEART DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE WEAKNESS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

EID: 0032820841     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199912020-00004     Document Type: Review

References (22)

1. HER2neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998 Aug; 16: 2659-71
2. HER2neu monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996 Mar; 14: 737-44
3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12
4. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 177-82
5. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894-904
6. Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11: 1936-42
7. Genentech I. FDA advisory committee recommends approval of first monoclonal antibody for metastatic breast cancer. In: Media Release 1998 Sep; [3pages], 2
8. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998 Jul 1; 58: 2825-31
9. HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89: 4285-9
10. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241-51
11. HER2 monoclonal antibody and cytokines. Anticancer Res 1996 Jan-Feb; 16: 433-6
12. Witters LM, Kumar R, Chinchilli VM, et al. Enhanced anti-proliferative activity of the combination of lamoxifen plus HER2-neu antibody. Breast Cancer Res Treat 1997 Jan; 42: 1-5
13. Lopez AM, Pegram MD, Landaw EM, et al. Models to assess combination therapy interactions: Optimal timing of anti-HER-2 antibody and doxorubicin in breast cancer [abstract]. 88th Annu Meet Am Assoc Cancer Res 1997 Apr 12: 605
14. Park JW, Colbern G, Nuijens A, et al. Increased levels of circulating HER2 ECD in response to anti-HER2 antibody therapy [abstract]. Breast Cancer Res Treat 1997 Oct; 46: 67
15. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin™ (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer [abstract]. 34th Proc Am Soc Clin Oncol 1998 May 16; 17: 97
16. Genentech Inc. Herceptin™ (Trastuzumab) Prescribing Information. San Francisco (CA), 1998
17. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial [abstract]. 34th Proc Am Soc Clin Oncol 1998 May 16; 17: 98
18. Baselga J, for the Herceptin International Investigator Group. Multinational studies of Herceptin™ (humanized anti-HER2 antibody) in HER+ metastatic breast cancer: Phase III of Herceptin plus chemotherapy (CRx) vs CRx alone in first-line and large phase II of Herceptin alone in advanced disease. Ann Oncol 9 (Suppl. 2)
19. Data on File. Hoffmann-La Roche, Basel. 1999
20. Norton L, Slamon D, Leyland Jones B, et al. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody herceptin in HER2-overexpressing metastatic breast cancer [abstract]. 35th Am Soc Clin Oncol 1999; 18: 127
21. Sliwkowski MX, Fox JA, Twaddell T et al. A humanized monoclonal antibody for the treatment of HER2 overexpressing breast cancer [abstract]. 87th Annu Meet Am Assoc Cancer Res 1996 Apr 20: 625-6
22. FDA clears Herceptin at record speed. Scrip Mag 1998; 2374: 20